Newsroom
Sorted by: Latest
-
RealPage Year End Analysis: Structural Drivers Remain Strong to Support Long-Term Rental Housing Demand
RICHARDSON, Texas--(BUSINESS WIRE)--RealPage Year End Analysis: Structural Drivers Remain Strong to Support Long-Term Rental Housing Demand...
-
Riskified Announces Ascend 2026: “Intelligence in Motion” for the Next Era of Ecommerce
NEW YORK--(BUSINESS WIRE)--Riskified announces Ascend 2026, a global ecommerce fraud and risk management summit series...
-
Five9 Appoints Amit Mathradas as Next Chief Executive Officer
SAN RAMON, Calif.--(BUSINESS WIRE)--Five9, Inc. (NASDAQ: FIVN) (“Five9” or the “Company”), provider of the Intelligent CX Platform, today announced that its Board of Directors (the “Board”) has appointed Amit Mathradas as the Company’s Chief Executive Officer (“CEO”) and a director, effective February 2, 2026. Mr. Mathradas will take on the role from Board Chairman Mike Burkland, whose decision to retire from the CEO position was announced in July. Mr. Burkland will continue to serve on the Boa...
-
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on December 15, 2025, the company granted restricted stock units (RSUs) with respect to 2,666 shares of the company’s common stock to 6 newly hired employees. These grants were made pursuant to the company’s 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company’s board of directors, and were made as a material inducement t...
-
Private Practice Platform Tebra Secures $250M to Accelerate AI Innovation
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Tebra closed $250M in financing led by Hildred to deploy AI across clinical documentation, billing automation, and practice marketing....
-
UWMC Announces Strategic Acquisition of TWO
PONTIAC, Mich. & NEW YORK--(BUSINESS WIRE)--UWM Holdings Corporation (“UWMC”) (NYSE: UWMC), the publicly traded indirect parent of United Wholesale Mortgage (“UWM”), the #1 overall mortgage lender in America, and Two Harbors Investment Corp. (“TWO”) (NYSE: TWO), an MSR-focused REIT and one of the largest servicers of conventional mortgages in the country through its wholly-owned subsidiary RoundPoint Mortgage Servicing LLC (“RoundPoint”), today announced that they have entered into a definitive...
-
The Toro Company Reports Fourth-Quarter and Full-Year Fiscal 2025 Financial Results
BLOOMINGTON, Minn.--(BUSINESS WIRE)--The Toro Company (NYSE: TTC), a leading global provider of solutions for the outdoor environment, today reported results for its fiscal fourth-quarter and full-year ended October 31, 2025. Fourth quarter net sales were $1.07 billion, compared to $1.08 billion in the same period of fiscal 2024. Full-year net sales were $4.51 billion, compared to $4.58 billion in fiscal 2024, with most of the difference due to prior year divestitures of non-core assets. Fourth...
-
BlackSky’s Third Gen-3 Enters Commercial Operations in Just Three Weeks Following Launch
HERNDON, Va.--(BUSINESS WIRE)--BlackSky successfully integrates its third Gen-3 satellite into commercial operations just three weeks following launch....
-
Limoneira Declares Quarterly Dividend
SANTA PAULA, Calif.--(BUSINESS WIRE)--On December 16, 2025, the Board of Directors of Limoneira Company (Nasdaq: LMNR), a diversified citrus growing, packing, selling and marketing company with related agribusiness activities and real estate development operations, declared a quarterly cash dividend of $0.075 per common share payable on January 16, 2026, to stockholders of record on December 30, 2025. About Limoneira Company Limoneira Company, a 132-year-old international agribusiness headquart...
-
Vistagen Announces Topline Results from PALISADE-3 Phase 3 Public Speaking Challenge Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that the PALISADE-3 Phase 3 study of intranasal fasedienol for the acute treatment of social anxiety disorder did not demonstrate a statistically significant improvement on the primary endpoint of change on the Subj...